Back to News
Market Impact: 0.2
Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Beactica Therapeutics selected BEA-28 as a preclinical candidate for its TEAD programme, an early-stage development milestone. The company said the programme aims to develop therapies for a range of aggressive conditions; the article excerpt provides no further candidate details or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks
- Analysis-Vietnam’s banks tap investors for $7 billion as economy runs red hot
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search